MUMBAI, India, Sept. 26 -- Intellectual Property India has published a patent application (202411019816 A) filed by Council Of Scientific And Industrial Research, New Delhi, on March 15, 2024, for 'amino acid and triazine based new poly.'
Inventor(s) include Gautam Panda; Saumya Ranjan Satrusal; Indranil Chatterjee; Souvik Barman; Kasim Ali; Sachin Kumar; Supriya Sinha; Sanjeev Meena; Jiaur Rahaman Gayen; Aamir Nazir; Smrati Bhadauria; and Dipak Datta.
The application for the patent was published on Sept. 26, under issue no. 39/2025.
According to the abstract released by the Intellectual Property India: "The invention relates to chiral amino acids as well as symmetrical diamino triazine substituted phthalazinones as Poly(ADP-ribose)polymerase (PARP) Inhibitors, process for the preparation and uses thereof as potential anticancer agents. The invention particularly relates to a process for the preparation of symmetrical for new. The compounds inhibited the growth and development of BRCA2 mutant cells with an IC50 value of the most active compounds in the range of 2-57 nM. The active compounds selectively induce cytotoxicity in BRCA2 mutant cancer cells compared to wild type cells with a mutant fold selectivity in range of 112- 2500-fold. The active compounds are capable of killing the BRCA mutated cancerous cells and show significant PARP activity as well as show low cytotoxicity to wild type cells. Most importantly, our hit molecules demonstrated approximately 50% or greater cell viability of mice HSPCs. This suggests an improved hematological safety profile of our hits, distinguishing them from FDA-approved PARP inhibitor Olaparib."
Disclaimer: Curated by HT Syndication.
